ライフサイエンスコーパス: HBcAg

1 HBcAg-primed Th cells efficiently produced interleukin-2

2 HBcAg-zDIII VLPs are shown to be highly immunogenic, as

3 he primary APCs for the hepatitis B core Ag (HBcAg) were B cells and not dendritic cells (DC).

4 the viral nucleocapsid hepatitis B core Ag (HBcAg), and its function is unknown.

5 ion, a novel retrovirus vector expressing an HBcAg-neomycin phosphotransferase II (HBc-Neo) fusion pr

6 HBcAg-specific Th cells into dual HBeAg- and HBcAg-expressing Tg recipient mice.

7 eferentially deplete inflammatory HBeAg- and HBcAg-specific Th1 cells that are necessary for viral cl

8 Knowledge of the binding site of our anti-HBcAg antibody bears on the molecular basis of the disti

9 ent forms of hepatitis B virus core antigen (HBcAg) and e antigen (HBeAg) were analyzed.

10 s, respectively referred to as core antigen (HBcAg) and e-antigen (HBeAg), share a sequence of 149 re

11 mino acid 97 (I97L) of the HBV core antigen (HBcAg) causes it to release immature genomes.

12 human hepatitis B virus (HBV) core antigen (HBcAg) has been found in chronic carriers worldwide.

13 ction of HBV DNA, RNA, and HBV core antigen (HBcAg) in hepatocytes.

14 Additionally, HBV core antigen (HBcAg) in vitro stimulation using peripheral blood monon

15 B virus (HBV) nucleocapsid or core antigen (HBcAg) is extremely immunogenic during infection and aft

16 ing different forms of the HBV core antigen (HBcAg) or e antigen (eAg) were found to induce antigen-s

17 histochemical detection of HBV core antigen (HBcAg) revealed >99% reduction in stained hepatocytes up

18 rrier based on the hepatitis B core antigen (HBcAg) that displays the ZIKV E protein domain III (zDII

19 eucine at amino acid 97 of HBV core antigen (HBcAg), lost the high stringency of selectivity in genom

20 n at the C terminus of the HBV core antigen (HBcAg), was speculated to secrete immature genomes.

21 nd non-crossreactive antigens: core antigen (HBcAg), which appears early in infection as assembled ca

22 antibodies is the hepatitis B core antigen (HBcAg); that these anti-bodies display a restricted vari

23 llular nucleocapsid (hepatitis core antigen [HBcAg]) and the secreted nonparticulate form (hepatitis

24 ith the viral capsid protein "core-antigen" (HBcAg), but has an additional 10-residue, hydrophobic, c

25 rs of a 183-residue protein, 'core antigen' (HBcAg).

26 (pg) RNA within the capsid of core antigens (HBcAgs) that each contains a flexible C-terminal tail ri

27 variants, we have characterized mutations at HBcAg codons 5, 38, and 60 via site-directed mutagenesis

28 Because HBcAg and the HBeAg are cross-reactive in terms of Th ce

29 , not to processing or presentation, because HBcAg/anti-HBc immune complexes can be efficiently prese

30 -NEO[6A3]-immunized H-2k mice abrogated both HBcAg-specific antibodies and in vitro-detectable cytoto

31 es expressing wild-type HBV (containing both HBcAg and HBeAg) are more susceptible to CTL-mediated cl

32 y direct HBcAg-biotin-binding studies and by HBcAg-specific T cell activation in vitro in cultures of

33 Cytokine production by HBcAg- and HBeAg-primed Th cells was consistent with the

34 Second, in vitro cytokine production by HBcAg- and HBeAg-primed Th cells was measured.

35 Humoral and CD4+ cellular HBcAg and/or HBeAg (HBc/eAg)-specific immune responses f

36 ciently removed from the membrane containing HBcAg using DNase I digestion and gradient wash with ure

37 The membrane strip containing HBcAg and a second membrane strip containing human serum

38 genic potential of the HBV precore and core (HBcAg) proteins, HBc/HBeAg-transgenic (Tg) mice crossed

39 ral nucleoprotein, the particulate HBV core (HBcAg) and the nonparticulate HBeAg, may preferentially

40 GC1alpha is a subtle increase in cytoplasmic HBcAg/p21 polypeptide translation, which shifts the equi

41 s apparent that the synthesis of cytoplasmic HBcAg/p21 above a critical threshold level is required f

42 This was demonstrated by direct HBcAg-biotin-binding studies and by HBcAg-specific T cel

43 This enables HBcAg-specific B cells from unprimed mice to take up, pr

44 and CD8(+) T cell priming with DNA encoding HBcAg does not require B cell APCs.

45 al and nonhelical loop regions of the entire HBcAg molecule is important for virion secretion.

46 he HBcAg is highly immunogenic, the existing HBcAg-based platform technology has a number of theoreti

47 lity of DC to function as APCs for exogenous HBcAg relates to lack of uptake of HBcAg, not to process

48 sidated pgRNA from nuclease was observed for HBcAg 1-171.

49 ter nuclease treatment was observed only for HBcAg 164 and 167.

50 subset of HepaRG cells stained positive for HBcAg at comparable or even higher mge.

51 studies with immunohistochemical stains for HBcAg and HBsAg also being negative.

52 Furthermore, HBcAg elicited primarily IgG2a and IgG2b anti-HBc antibo

53 Furthermore, HBcAg-specific CD4(+) and CD8(+) T cell priming with DNA

54 This study revealed three phenotypes of HBe/HBcAg-specific T-cell tolerance: (i) profound T-cell tol

55 cells was also examined by transferring HBe/HBcAg-specific Th cells into dual HBeAg- and HBcAg-expre

56 In HBcAg dimers, the subunits pair by forming a four-helix

57 cleocapsid spikes differentiated contacts in HBcAg for the two binding domains in L-HBsAg and implied

58 -Tg mice but elicited a weak CTL response in HBcAg-Tg mice.

59 y greater in HBeAg-Tg recipient mice than in HBcAg-Tg mice.

60 of recombinant retrovirus vectors to induce HBcAg- and eAg-specific CTL responses may prove benefici

61 For example, during many chronic infections, HBcAg is the only antigen capable of eliciting an immune

62 creted HBeAg (HBe[5A2]), or an intracellular HBcAg-neomycin phosphoryltransferase fusion protein (HBc

63 vectors induced expression of intracellular HBcAg (HBc[3A4]), secreted HBeAg (HBe[5A2]), or an intra

64 cantly more efficient than the intracellular HBcAg at eliciting T-cell tolerance.

65 Full-length (HBcAg(183)), truncated (HBcAg(149)), and the nonparticul

66 istidine tagging at the C terminus of mutant HBcAg, which is presumably in the capsid interior.

67 ell activation in vitro in cultures of naive HBcAg-specific T cells and resting B cell subpopulations

68 capsids of HBcAg 154, 164, and 167, but not HBcAg 183, exhibited nuclease sensitivity; however, caps

69 Notably, HBcAg-zDIII VLPs-elicited antibodies did not enhance the

70 Surprisingly, the nuclear HBcAg of mutants I97E and I97W, produced from either a r

71 ledge, this is the first report of nucleolar HBcAg in culture.

72 of this study was to evaluate the ability of HBcAg- and HBeAg-specific genetic immunogens to induce H

73 an immune response, and nanogram amounts of HBcAg elicit antibody production in mice.

74 Binding of HBcAg particles by L-HBsAg displayed two widely differin

75 capsidated in Escherichia coli by capsids of HBcAg 154, 164, and 167, but not HBcAg 183, exhibited nu

76 by disulfide bonding of the last cysteine of HBcAg.

77 APC, explain the enhanced immunogenicity of HBcAg, and may have relevance for the induction and/or m

78 The immunogenicity of HBcAg, in contrast to that of HBeAg, did not require the

79 r apoptotic, suggesting that the presence of HBcAg in the nucleolus may perturb cytokinesis.

80 idate the structure-function relationship of HBcAg at amino acid 97, we systematically replaced the i

81 re constructed of dimers resembling those of HBcAg capsids.

82 mmunogen characteristics similar to those of HBcAg, comparative antigenicity and immunogenicity studi

83 exogenous HBcAg relates to lack of uptake of HBcAg, not to processing or presentation, because HBcAg/

84 unity problem that is inherent in the use of HBcAg for human vaccine development.

85 The effect of circulating HBeAg on HBcAg-specific Th1 cells was also examined by transferri

86 d clearance than hepatocytes expressing only HBcAg suggest that the HBeAg-negative variant may have a

87 hepatitis B virus core antigen polypeptide (HBcAg/p21) synthesis, it mediates a dramatic increase in

88 primed mice to take up, process, and present HBcAg to naive Th cells in vivo and to T cell hybridomas

89 no acid 97 of the HBV core (capsid) protein (HBcAg).

90 The hepatitis B virus core protein (HBcAg) is a uniquely immunogenic particulate antigen and

91 to MHBs, a VLV expressing HBV core protein (HBcAg) neither induced a CD8 T cell response in mice nor

92 The particulate hepatitis core protein (HBcAg) represents an efficient carrier platform with man

93 A crude Hepatitis B virus core protein (HBcAg) was separated using polyacrylamide gel electropho

94 the virus envelope and nucleocapsid protein (HBcAg).

95 urpose, mice were immunized with recombinant HBcAg and HBeAg in the presence and absence of adjuvants

96 d B1b cells more efficiently present soluble HBcAg to naive CD4(+) T cells than splenic B2 cells.

97 n immunogenicity to or more immunogenic than HBcAg at the B-cell and T-cell levels; (ii) major histoc

98 itopes at a greater number of positions than HBcAg.

99 The results indicate that HBcAg preferentially, but not exclusively, elicits Th1-l

100 and IgM anti-HBc antibodies, indicating that HBcAg is the target of a germline human V(H) gene.

101 Although the HBcAg is highly immunogenic, the existing HBcAg-based pl

102 t T-cell tolerance between the HBeAg and the HBcAg and the clonal heterogeneity of HBc/HBeAg-specific

103 Both the HBcAg- and HBeAg-specific plasmids primed comparable imm

104 reveal a structure-function relation for the HBcAg, confirm that B cells can function as primary APC,

105 Our analysis of how the HBcAg is presented to the immune system revealed that th

106 The pleiotropic effects of the HBcAg codon 97 mutation were observed consistently in se

107 inal binding domain contacts the tips of the HBcAg spikes.

108 The HBeAg capsids are less regular than the HBcAg capsids; nevertheless, cryo-electron microscopy re

109 ented to the immune system revealed that the HBcAg binds to specific membrane Ig (mIg) antigen recept

110 re not significantly cross-reactive with the HBcAg at the antibody level (however, the nonparticulate

111 h oppositely charged C-terminal tails of the HBcAgs, and that the net charge of the capsid and C-term

112 synergistically to high-affinity binding to HBcAg, but disruption of either of these segments result

113 and enhance the adaptive immune response to HBcAg and have important implications for the use of hep

114 The T-cell proliferative response to HBcAg did not differ between the three groups.

115 ers have higher PBMCs IFN-gamma secretion to HBcAg stimulation (P= .0002).

116 the wild-type HBV and mutants with truncated HBcAg C-termini.

117 Full-length (HBcAg(183)), truncated (HBcAg(149)), and the nonparticulate HBeAg were screened

118 this colocalization occurred with wild-type HBcAg only to a limited extent.

119 the residues necessary for association with HBcAg.

120 iculocyte lysates and their interaction with HBcAg was examined with an immunoprecipitation assay and

121 teins are only partially cross-reactive with HBcAg at the CD4+ T-cell level, depending on MHC haploty

122 However, the ssRNA contained within HBcAg(183) does function as a TLR-7 ligand, as demonstra

123 ast, and mammalian ssRNA encapsidated within HBcAg(183) all function as TLR-7 ligands.